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Abstract 
Background: Short-course oral corticosteroids are routinely used to treat acute asthma and 
croup. We evaluated their tolerability and palatability in Saudi Arabian (SA) and UK children.  
Methods: Prospective observational/interview study (three months in each country). 
Palatability was evaluated using a five-point facial scale and tolerability by direct questioning 
of patient/parents. 
Results: In SA, of 122 patients (2–10years) recruited: 52 received prednisolone base tablets; 
37 prednisolone sodium phosphate syrup; 33 dexamethasone elixir. In the UK, of 133 patients 
(2–16years): 38 received prednisolone base tablets (mainly crushed and dispersed); 42 
prednisolone sodium phosphate soluble tablets; 53 dexamethasone sodium phosphate oral 
solution. 
In both countries dexamethasone had the highest palatability scores (SA mean: 1.97; UK 
mean: 3) and prednisolone base tablets the lowest (SA mean: 1.12; UK mean: 1.39). 
Palatability scores improved for all formulations of prednisolone with each subsequent daily 
dose. 
In SA prednisolone base tablets were associated with more nausea (24 vs 7 patients) and 
vomiting (5 vs 0) than sodium phosphate syrup (P=0.008 and P=0.073 respectively). In the 
UK vomiting occurred more frequently with prednisolone base (8) than sodium phosphate 
soluble tablets (2) (P=0.041).  
In both centres dexamethasone was associated with less side effects. Vomiting (1 vs 0 
patients), nausea (7 vs 3) and abdominal pain (10 vs 8) occurred more with dexamethasone 
sodium phosphate solution than dexamethasone elixir. 
Conclusions: Dexamethasone sodium phosphate solution was the most palatable 
preparation. Prednisolone base tablets were rated least palatable and were least well 
tolerated. Palatability scores improved with each dose taken.  
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Introduction 
Corticosteroids are widely used to treat a variety of medical conditions. The palatability and 
tolerability of medication is an important factor influencing adherence to medication particularly 
in children. The European Medicines Agency advises that medicinal products should be made 
in formulations with an acceptable taste for children [1]. Oral corticosteroids often have a bitter 
taste and are also associated with a wide variety of adverse effects [2]. Tolerability relates to 
several factors including taste and adverse symptoms such as vomiting, nausea and 
abdominal pain that can affect quality of life and willingness to continue treatment [3].   
A recent systematic review found that gastrointestinal disorders including vomiting, nausea 
and abdominal pain were the most common side effects of oral corticosteroids given in short 
courses [4]. In the studies where formulation was discussed prednisolone sodium phosphate 
solution had a lower risk of vomiting than both prednisolone (base) solution and oral 
dexamethasone [4]. Only one study, compared both the palatability and tolerability of oral 
prednisolone and dexamethasone. This study found that dexamethasone was more likely to 
cause vomiting than prednisolone [5]. 
We describe a prospective observational study in the paediatric wards of Gurayat General 
Hospital (GGH) in Saudi Arabia (SA) and Derbyshire Children's Hospital in the UK to evaluate 
and compare the tolerability and palatability of routinely used preparations of oral prednisolone 
for asthmatic patients and oral dexamethasone for croup patients.   
 
Methods 
The study was conducted in the children's emergency department (ED) of the two hospitals. 
Children suffering from asthma or croup, prescribed oral prednisolone or dexamethasone and 
able to understand the study’s palatability scale and communicate their response were 
approached for consent. The drugs and products administered were in accordance with 
standard practice in each department. Choice of product and routine care of the patients was 
unaffected by the study.  
In SA, patients were treated with prednisolone base 5mg tablets (Gupisone®, Julphar, United 
Arab Emirates), prednisolone sodium phosphate 15mg/5mL syrup (Predo®, Jazeera 
Pharmaceutical Industries, SA) and dexamethasone 0.5mg/5mL elixir (Decadron®, Algorithm 
pharmaceutical manufacturers, Lebanon). The study was conducted for three months 
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between 1st February and 30 April 2015 in GGH. It included only children ≤12 years of age as 
paediatric admissions in SA are limited to this age. 
In the UK, children (2–18 years) were treated with prednisolone base 5mg tablets 
(Prednisolone, Actavis UK Limited, UK), prednisolone sodium phosphate 5mg soluble tablets 
(Soluble Prednisolone, Amdipharm UK Limited, UK) and dexamethasone sodium phosphate 
2mg/5ml solution (Dexamethasone, Focus Pharmaceuticals Ltd, UK). The study was 
conducted in the children's Accident & Emergency (A&E) department and hospital wards, for 
three months between 15 September and 21 December 2015. 
We used a five-point facial hedonic scale to assess palatability in both countries, as used 
previously in studies comparing the taste of analgesic and corticosteroid preparations in 
children [6][7]. The scale was explained to the patient and parent by the researcher who were 
then asked to rate the palatability of the medication within ten minutes of taking the drug where 
possible, by pointing to the appropriate face. To evaluate taste in younger patients who were 
unable to self-report, parents were asked to help in interpreting what their child thought of the 
taste of the medication.  
Tolerability (nausea, vomiting and abdominal pain) as reported by the parent/patients in 
response to direct questions, was documented 30–60 minutes after each drug administration. 
To evaluate nausea in younger patients unable to self-report this symptom, their parents were 
asked if they had observed any change in their child’s wellbeing which suggested them to be 
experiencing nausea including dizziness, lethargy or being cold and clammy.    
Palatability and tolerability ratings were obtained from patients after each dose of medication 
until the course ended. The researcher contacted the parents by telephone if the patient had 
been discharged, alternatively parents were given the option to complete the data collection 
form themselves and return it by post using a prepaid envelope.  
The data collection form (DCF)  used for each patient was a modification of questions used in 
two previous studies of acceptability and/or side effects in children receiving short course 
prednisolone for the treatment of acute asthma [8][9]. (Figure 1) 
Percentages and Chi-square testing were used for categorical variables to compare between 
tastes of different dosage forms and the tolerability of each drug. Categorical data were 
compared using the Chi-square or Fisher’s exact test where appropriate. The McNemar-
Bowker test was used to compare among the same group of patients how the taste score 
changed between different days. A significance level of P<0.05 was accepted as significant 
for all the tests. 
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In Saudi Arabia, ethical approval (Ref: 620/13/54) was obtained from the hospital Quality and 
Patient Safety Committee (QPSC) on 23 December 2014. In the UK, ethical approval (REC 
Ref: 15/EM/0057) was obtained from East Midlands - Derby Research Ethics Committee on 
19 March 2015. 
 
Results 
Overview  
In SA, 141 children were approached for the study. 19 children were not recruited: 11 because 
the parents refused to take part and eight children were missed for observation (Supplement 
Figure 1). 122 children were enrolled to the study (Table 1). Most of them were asthmatic 
patients (89) aged 2–10 years and the others had croup (33) aged 2–5.5 years. The asthmatic 
patients received two formulations of prednisolone (52 received prednisolone base soluble 
tablets and 37 received prednisolone sodium phosphate syrup). The croup patients all 
received oral dexamethasone elixir. Prednisolone base tablets were crushed and dispersed 
in water in all cases. Most patients were aged between 2 and 5 years old. The dose between 
prednisolone groups was almost the same. Around half of patients in the prednisolone groups 
had received oral steroids in previous disease episodes, while in the dexamethasone group 
no patients had oral steroids before. 
In the UK, a total of 147 children were approached. 14 children were not recruited: six because 
the parents refused to take part and eight children were missed for observation (Supplement 
Figure 2). 133 children were enrolled to the study (Table 1). Most of them were asthmatic 
patients (80) aged 2–16 years and the others had croup (53) aged 2–10 years. The asthmatic 
patients received two formulations of prednisolone (38 received prednisolone base tablets and 
42 received prednisolone sodium phosphate soluble tablets), and the croup patients all 
received oral dexamethasone sodium phosphate solution. Crushed prednisolone base tablets 
and prednisolone sodium phosphate soluble tablets were dispersed/dissolved in water and a 
few patients followed administration by a drink of blackcurrant juice if the patient chose to 
when offered this by a nurse. Only five patients received solid prednisolone base tablets. Most 
patients were aged between 2 and 5 years old in all corticosteroid groups. The dose between 
prednisolone groups was almost the same. Most patients in the prednisolone groups had 
received oral steroids previously, while in the dexamethasone group most patients had not 
received oral steroids before. 
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Palatability  
In SA, the majority of the children on the first day disliked the taste of the medicines (100% of 
prednisolone base tablet group, 89% of prednisolone sodium phosphate group and 76% of 
dexamethasone group) and no patients stated that they liked the taste on any day (Table 2). 
Prednisolone base was disliked the most (89%) and dexamethasone was disliked the least 
(27%) (P ˂ 0.0001). Both prednisolone base tablets and prednisolone sodium phosphate syrup 
were rated significantly more palatable day by day (Supplement Table 1). 
The children who had received oral corticosteroids before (experienced patients), reported 
different palatability scores to the children who received the medicine for the first time (naïve 
patients). These differences in taste scores were statistically significant on the first three days 
(Figure 2).  
In the UK, the majority of the children on the first day disliked the taste of the medicines (90% 
of prednisolone base tablet group, 62% of prednisolone sodium phosphate group and 34% of 
dexamethasone group) (Table 3). On day 1 most patients that received prednisolone base 
(77%) disliked the medication very much as did 36% of the prednisolone sodium phosphate 
group. Only 6% of patients disliked dexamethasone very much (P ˂ 0.0001). Both prednisolone 
base tablets and prednisolone sodium phosphate soluble tablets were rated significantly more 
palatable day by day (Supplement Table 1). 
The children who had received oral corticosteroids before (experienced patients), reported 
different palatability scores to the children receiving the medicine for the first time (naïve 
patients). These differences in taste scores were statistically significant on day 3 only (Figure 
2).  Most treatment naïve croup patients disliked the taste a little (40%) or were neutral (40%), 
while 33.3% of experienced patients were neutral, 33.3% liked the taste a little and 17% liked 
the taste very much. The differences were statistically significant (P = 0.021) 
 
Tolerability 
In SA, five patients in the prednisolone base group experienced vomiting, while no patients 
experienced vomiting in the prednisolone sodium phosphate group (P=0.073). Nausea was 
reported among almost half of patients taking the prednisolone base formulation (24 patients). 
This was significantly more frequent than with the prednisolone sodium phosphate formulation 
(OR=3.67, 95% CI, 1.26, 11.58, P=0.008). Abdominal pain, however was reported more 
frequently in patients taking the prednisolone sodium phosphate formulation (n=13) than in 
patients taking the prednisolone base formulation (n=8) (OR=2.9, 95% CI, 1.1, 8.1, P=0.031). 
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The patients who received dexamethasone experienced nausea and abdominal pain at rates 
of 9% and 24% respectively of the total 33 patients, but no patients experienced vomiting. 
Other side effects were also reported. Behavioural change and sleep disturbance were the 
most common side effects. They occurred much more frequently with prednisolone base 
tablets than prednisolone sodium phosphate syrup, behavioural change (9 vs 2) and sleep 
disturbance (9 vs 3). The differences were however not significant (p = 0.11 and p = 0.34 
respectively).   
In the UK, eight patients in the prednisolone base group and two patients in the prednisolone 
sodium phosphate group experienced vomiting (P=0.041). Nausea was significantly more 
frequent being reported by almost half the patients taking the prednisolone base formulation 
(17) compared to a third of patients taking prednisolone sodium phosphate (11) (OR=2.3, 95% 
CI, 0.8, 6.5, P=0.103). Abdominal pain was reported more frequently in patients taking the 
prednisolone base formulation (n=10) than with the prednisolone sodium phosphate 
formulation (n=7) (OR=1.8, 95% CI, 0.5, 6.3, P=0.413). The patients who received 
dexamethasone experienced vomiting, nausea and abdominal pain at rates of 1.9%, 13.2% 
and 18.9% respectively, among the total number of patients (53 patients). Other side effects 
were also reported. Behavioural change and sleep disturbance were the most common side 
effects. They occurred more frequently with prednisolone base tablets than prednisolone 
sodium phosphate soluble tablets, behavioural change (11 vs 9) and sleep disturbance (6 vs 
2). The differences were however not significant (p = 0.45 and p = 0.14 respectively).   
 
 
Discussion 
Taste affects the acceptability of medication and may affect adherence. In these two countries 
children consistently reported that dexamethasone tasted better than prednisolone; 
prednisolone base tasted the worst and prednisolone sodium phosphate was more palatable 
than prednisolone base. Others have also demonstrated differences in the palatability of 
different formulations [10][11]. 
Nausea and vomiting were more frequent with prednisolone base tablets in both countries. 
Prednisolone sodium phosphate syrup resulted in more abdominal pain in the SA children. 
Others have demonstrated increased vomiting with prednisolone base tablets [10]. This 
variation of reported side effects shows that the formulation is important. Most children in both 
countries required the prednisolone base tablets to be dispersed in water prior to 
administration as they could not swallow whole tablets. This may have reduced the tolerability. 
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Children in both countries who received dexamethasone were more likely to experience 
abdominal pain rather than nausea and vomiting. A previous meta-analysis also found that 
vomiting was more frequent with prednisolone compared with dexamethasone [4].  
If improved taste and less side effects were the only deciding factors, prednisolone sodium 
phosphate would appear to be the best choice for asthmatic children of the commonly used 
medications but other factors also need to be considered. Oral dexamethasone has been 
shown to be an effective alternative to oral prednisolone in the treatment of acute asthma in 
children [12]. Keeney at al suggested that two days of oral dexamethasone is similarly effective 
to five days of oral prednisolone with evidence that dexamethasone might be better tolerated 
and require shorter duration of therapy [13]. Since dexamethasone was the overall most 
palatable and best tolerated preparation when given as a single dose for croup this may 
suggest that it would be a useful alternative in the treatment of children with acute asthma 
episodes.  
Another factor which must also be considered is the cost of the medication with prednisolone 
sodium phosphate tablets costing sixty times more than prednisolone base tablets in the UK 
(Supplement Table 2) [14]. As a result many centres in the UK have moved to using 
prednisolone base tablets despite patients finding them less palatable and tolerable. Annual 
cost savings of up to £44,000 in a single UK hospital have been predicted [15].   
Taste ratings improved throughout the duration of the treatment. In addition children who had 
received oral corticosteroids before (experienced patients) reported significantly higher (more 
favourable) palatability scores than children who received the medicine for the first time (naïve 
patients) in both countries studied. Research suggests that the physiology and neurobiological 
mechanisms underlying the taste function mean that the impression of taste changes with time 
and experience and leads to adaptation of taste perception [16]. The experienced patient who 
is familiar with the medication taste may therefore have adapted and started to accept it. This 
may also explain our findings that the taste ratings of all medications improved in both 
countries day by day. It is also possible that as treatment becomes effective and children start 
to feel better they become more cooperative and tolerant. No other studies identified however 
have made this observation of increased tolerability with time or with experience for these 
drugs. 
In conclusion dexamethasone was rated more palatable than prednisolone. For asthmatic 
patients, prednisolone base tablets were rated the least palatable preparation and were also 
the least well tolerated. Prednisolone sodium phosphate was associated with a significantly 
lower incidence of nausea and vomiting and better taste score, compared to prednisolone 
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base. Best practice suggests prednisolone sodium phosphate or dexamethasone should be 
used.  
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What is already known on this topic? 
 Oral prednisolone and dexamethasone are widely used in children to treat conditions 
such as asthma and croup.  
 The taste of prednisolone in particular is an issue which may affect adherence to 
treatment in children. 
 
 
What this study adds 
 Dexamethasone was rated as more palatable than prednisolone in two different 
countries.   
 Prednisolone sodium phosphate seems to cause significantly less nausea and 
vomiting than prednisolone base and is rated more palatable. 
 Experienced patients gave better taste scores for all formulations compared with naïve 
patients.  
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Figure 1  Data collection form 
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Figure 2:  Mean taste scores of prednisolone base and prednisolone sodium phosphate according to drug history in SA and in the UK 
 
Abbreviations: Pred. Base= prednisolone base, Pred. Na3PO4= prednisolone sodium phosphate, E=Experienced patients, N=Naïve patients. 
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Table 1   Demographics of recruited children 
Total no. of Patients 
N = 255 
SA UK 
Prednisolone 
Base Tablet 
N = 52 
Prednisolone 
Sodium Phosphate 
Syrup 
N = 37 
Dexamethasone 
Elixir 
N = 33 
Prednisolone 
Base Tablet 
N = 38 
Prednisolone Sodium 
Phosphate Soluble 
Tablet 
N = 42 
Dexamethasone 
Sodium Phosphate 
Solution 
N = 53 
Age  (year) 
Median 4.5 4 3.5 5 4 3 
Range (2 – 10) (2 – 10) (2 – 5.5) (2.4 – 16) (2 – 14) (2 – 10) 
Interquartile 
Range (IQR) 
3 – 6 3 – 5 3 – 4.75 3.38 – 7.5 3 – 7 2.5 – 5 
Gender 
Male (%) 34 (65.4) 18 (48.6) 18 (54.5) 22 (58) 29 (69) 28 (53) 
Female (%) 18 (34.6) 19 (51.4) 15 (45.5) 16 (42) 13 (31) 25 (47) 
Weight (kg) 
Median 18 15 14 20 17.8 17 
Range (10 – 35) (10 – 30) (10 – 21) (11.5 – 77) (10.3 – 80) (12 – 48.7) 
Dose 
(mg/kg/day) 
Median 2 2 0.3 1.2 1.1 0.2 
Range (1.5 – 2) 2 (0.2 – 0.4) (1.2 – 2) (0.4 – 2) (0.1 – 0.6) 
Dose Duration 
(day) 
Median 3 3 1 3 3 1 
Range (1 – 5) (3 – 5) 1 (1 – 5) (1 – 5) 1 
Received oral 
steroids before 
Yes 24 20 0 29 27 18 
No 28 17 33 9 15 35 
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Table 2  Palatability of oral corticosteroids in SA 
Total no. of Patients 
N = 122 
N 
Taste of medication 
Mean of taste 
score (1-5)¶ 
S.D. 
95% Confidence Interval 
for Mean 
P-value Dislike very 
much (%) 
Dislike a 
little (%) 
Not sure or 
neutral (%) 
Day 1 N = 122 
Prednisolone base 52 46 (89) 6 (11) 0 1.12 0.32 (1.03, 1.21) 
˂0.0001*± 
Prednisolone 
Sodium Phosphate 
37 18 (49) 15 (40) 4(11) 1.62 0.68 (1.39, 1.85) 
Dexamethasone 33 9 (27) 16 (49) 8 (24) 1.97 0.73 (1.71, 2.23) 
Day 2 N = 82 
Prednisolone base 45 29 (64) 13 (29) 3 (7) 1.42 0.62 (1.24, 1.61) 
˂0.0001* Prednisolone 
Sodium Phosphate 
37 4 (11) 25 (68) 8 (21) 2.11 0.57 (1.92, 2.30) 
Day 3 N = 74 
Prednisolone base 42 17 (40) 22 (53) 3 (7) 1.67 0.61 (1.48, 1.86) 
˂0.0001* Prednisolone 
Sodium Phosphate 
32 1 (3) 18 (56) 13 (41) 2.38 0.55 (2.18, 2.57) 
Day 4 N = 11 
Prednisolone base 10 1 (10) 7 (70) 2 (20) 2.1 0.57 (1.69, 2.51) 
0.364± Prednisolone 
Sodium Phosphate 
1 0 0 1 (100) 3 - - 
Day 5 N = 5 Prednisolone base 5 0 3 (60) 2 (40) 2.4 0.54 - - 
* Significant results, ± Fisher’s exact test. ¶ 1=Dislike very much, 2=Dislike a little, 3=Not sure, 4=Like a little, 5=Like very much 
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Table 3   Palatability of oral corticosteroids in the UK 
Total no. of Patients 
N = 133 
N 
Taste of medication Mean of 
taste score 
(1-5)¶ 
S.D. 
95% Confidence 
Interval for Mean 
P-value Dislike very 
much (%) 
Dislike a 
little (%) 
Not sure or 
neutral (%) 
Like a 
little (%) 
Like very 
much (%) 
Day 1 N = 133 
Prednisolone base 38 29 (77) 5 (13) 2 (5) 2 (5) 0 1.39 0.82 (1.12, 1.67) 
˂0.0001* 
Prednisolone 
Sodium Phosphate 
42 15 (36) 11 (26) 10 (24) 5 (12) 1 (2) 2.19 1.1 (1.84, 2.54) 
Dexamethasone 53 3 (6) 15 (28) 20 (38) 9 (17) 6 (11) 3 1.1 (2.7, 3.3) 
Day 2 N = 55 
Prednisolone base 31 19 (61) 6 (20) 5 (16) 1 (3) 0 1.61 0.88 (1.29, 1.94) 
0.009* Prednisolone 
Sodium Phosphate 
24 4 (17) 14 (58) 4 (17) 1 (4) 1 (4) 2.21 0.93 (1.81, 2.6) 
Day 3 N = 55 
Prednisolone base 31 13 (42) 8 (26) 8 (26) 2 (6) 0 1.97 0.98 (1.61, 2.33) 
0.019* Prednisolone 
Sodium Phosphate 
24 1 (4) 13 (54) 7 (30) 2 (8) 1 (4) 2.54 0.88 (2.71, 2.91) 
Day 4 N = 9 
Prednisolone base 6 3 (49) 1 (17) 1 (17) 1 (17) 0 2 1.27 (0.67, 3.33) 
0.131 Prednisolone 
Sodium Phosphate 
3 0 3 (100) 0 0 0 2 - - 
Day 5 N = 9 
Prednisolone base 6 3 (49) 1 (17) 1 (17) 1 (17) 0 2 1.27 (0.67, 3.33) 
0.131 Prednisolone 
Sodium Phosphate 
3 0 3 (100) 0 0 0 2 - - 
* Significant results. ¶ 1=Dislike very much, 2=Dislike a little, 3=Not sure, 4=Like a little, 5=Like very much.  
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Supplement Table 1  Palatability changes with days of treatment  
Compare Days 
Prednisolone base Prednisolone Sodium Phosphate 
SA UK SA UK 
Mean of taste P-value Mean of taste P-value Mean of taste P-value Mean of taste P-value 
Day 1 vs Day 2 1.12 vs 1.42 0.025* 1.39 vs 1.61 0.061 1.62 vs 2.11 0.001* 2.19 vs 2.21 0.075 
Day 2 vs Day 3 1.42 vs 1.67 0.004* 1.61 vs 1.97 0.019* 2.11 vs 2.38 0.075 2.21 vs 2.54 0.136 
Day 1 vs Day 3 1.12 vs 1.67 ˂0.0001* 1.39 vs 1.97 0.01* 1.62 vs 2.38  ˂0.0001* 2.19 vs 2.54 0.0451* 
* Significant results, McNemar-Bowker test.  
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Supplement Table 2 UK cost of different corticosteroid formulations 
Oral corticosteroids 
(Drug Tariff price) [14] 
Price / unit 
Treatment cost of one dose for child weighing 20kg receiving 
2mg/kg/day of prednisolone or 0.3mg/kg/day of dexamethasone 
Prednisolone base 
Prednisolone 5mg tablets 3p/tablet £0.24 
Prednisolone 5mg/5ml oral 
solution unit dose 
23p/ml £9.20 
Prednisolone 10mg/ml oral 
solution sugar free 
£1.85/ml £7.40 
Prednisolone sodium 
phosphate 
Prednisolone 5mg soluble 
tablets 
£1.78/tablet £14.24 
Dexamethasone 
Dexamethasone 2mg soluble 
tablets sugar free 
68p/tablet £2.04 
Dexamethasone 2mg tablets 98p/tablet £2.94 
Dexamethasone 10mg/5ml 
oral solution sugar free 
63p/ml £1.89 
Dexamethasone 2mg/5ml oral 
solution sugar free 
28p/ml £4.20 
 
  
22 
 
Supplement Figure 1  Enrolment chart for Saudi Arabia children 
 
Supplement Figure 2  Enrolment chart for United Kingdom children 
 
 
23 
 
 
